Study identifier:D3720C00012
ClinicalTrials.gov identifier:NCT01664065
EudraCT identifier:N/A
CTIS identifier:N/A
An Open-label, Nonrandomised, Phase I Study to Assess the Pharmacokinetics of Ceftaroline After Intravenous Administration of aSingle Dose of Ceftaroline Fosamil (200 mg) to Patients with End-stage Renal Disease Undergoing Haemodialysis when Compared to a Single Dose of Ceftaroline Fosamil (600 mg)
Renal disease
Phase 1
Yes
200 mg Ceftaroline fosamil, 600 mg Ceftaroline fosamil
All
15
Interventional
18 Years - 75 Years
Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verified 01 Feb 2016 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: AZ drug: A 200 mg Ceftaroline fosamil 1h infusion | Drug: 200 mg Ceftaroline fosamil 1 h infusion |
Experimental: AZ drug: B 600 mg Ceftaroline fosamil 1h infusion | Drug: 600 mg Ceftaroline fosamil 1 h infusion |